We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
ESC 2024 - Deepak Bhatt gives an overview of the kidney results from the EMPACT-MI trial among patients with acute MI. “What we found in fact was quite reassuring, there was no excess of adverse kidney events with empagliflozin versus placebo”, says Deepak Bhatt.
This video was recorded during the ESC Congress 2024 in London, UK.
Deepak Bhatt, MD is Director of Mount Sinai Heart, New York, NY, US. He also serves as the first-ever Dr. Valentin Fuster Professor of Cardiovascular Medicine.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 11 September 2024
ESC 2024 - Deepak Bhatt gives an overview of the kidney results from the EMPACT-MI trial among patients with acute MI. “What we found in fact was quite reassuring, there was no excess of adverse kidney events with empagliflozin versus placebo”, says Deepak Bhatt.
This video was recorded during the ESC Congress 2024 in London, UK.
Deepak Bhatt, MD is Director of Mount Sinai Heart, New York, NY, US. He also serves as the first-ever Dr. Valentin Fuster Professor of Cardiovascular Medicine.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 11 September 2024
Stay current with the best on medical education
